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Abstract The quality of assessment of non-adherence to
treatment in hypertensive is poor. Within this review, we dis-
cuss the different methods used to assess adherence to blood-
pressure-lowering medications in hypertension patients.
Subjective reports such as physicians’ perceptions are inaccu-
rate, and questionnaires completed by patients tend to overre-
port adherence and show a low diagnostic specificity. Indirect
objective methods such as pharmacy database records can be
useful, but they are limited by the robustness of the recorded
data. Electronic medication monitoring devices are accurate
but usually track adherence to only a single medication and
can be expensive. Overall, the fundamental issue with indirect
objective measures is that they do not fully confirm ingestion
of antihypertensive medications. Detection of antihyperten-
sive medications in body fluids using liquid chromatogra-
phy–tandem mass spectrometry is currently, in our view, the
most robust and clinically useful method to assess non-
adherence to blood-pressure-lowering treatment. It is particu-
larly helpful in patients presenting with resistant, refractory or
uncontrolled hypertension despite the optimal therapy. We
recommend using this diagnostic strategy to detect non-
adherence alongside a no-blame approach tailoring support
to address the perceptions (e.g. beliefs about the illness and
treatment) and practicalities (e.g. capability and resources)
influencing motivation and ability to adhere.
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Introduction
Hypertension affects more than a billion patients worldwide
and is the leading cause of global disease burden, ahead of
smoking and obesity [1]. High blood pressure (BP) is one of
the most important modifiable risk factors of cardiovascular
disease. Although potent antihypertensive medications are
available, BP is optimally controlled in only half to two thirds
of patients [2, 3]. One potential explanation for such a low rate
of BP control is that antihypertensive medications are not
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taken as prescribed or not taken at all [4–6]. Non-adherence is
defined as ‘the extent to which a person’s behaviour—taking
medication, following a diet, and/or executing lifestyle chang-
es, corresponds with agreed recommendations from a health
care provider’ [7•]. Non-adherence to antihypertensive thera-
py is known to correlate with poor cardiovascular outcomes. It
is the main reason for treatment failure and repeated hospital
admissions [8]. Conversely, good adherence to blood-pressure
-lowering therapy is associated with a reduction of adverse
cardiovascular outcomes [9•]. Unfortunately, up to 40% of
clinical appointments fail to address adherence [10, 11•].
Furthermore, patients are frequently reluctant to volunteer in-
formation about suboptimal adherence to treatment [12].
Resistant hypertension is defined as uncontrolled BP de-
spite the use of three different classes of antihypertensive ther-
apy at maximally tolerated doses, one of which is a diuretic
[13]. The prevalence of resistant hypertension is estimated at
10–20% in patients with elevated BP [13–16]. Patients with
resistant hypertension have a higher incidence of cardiovas-
cular disease and mortality than the general hypertensive pop-
ulation [13]. Without an appropriate diagnostic approach, re-
sistant hypertension is often difficult to differentiate from
pseudo-resistant hypertension (apparent resistant hyperten-
sion) [14]. The latter is usually caused by white coat effect/
hypertension, suboptimal choice/doses of antihypertensive
medications and/or non-adherence to treatment [17]. Our re-
cent analysis suggests that non-adherence is the dominant type
of pseudo-resistant hypertension in patients referred for renal
denervation [18•]. Thus, addressing non-adherence is of crit-
ical importance in the management of patients diagnosed with
resistant hypertension [6, 19].
How to Diagnose Non-Adherence
Subjective Methods
Physician Perception and Patient Self-Reported Methods
Research has demonstrated that physicians are generally not
good judges of whether their patients are taking their medica-
tion as prescribed. Indeed, physicians’ perception of non-
adherence correlated with an objective measure in less than
40% of cases. Moreover, 40% of diagnoses of non-adherence
based on clinical judgment results in treatment escalation that
through augmentation of polypharmacy may further compro-
mise adherence [20]. Increasing the number/doses of antihy-
pertensive medications despite an impression of non-
adherence implies that the confidence of physicians in the
diagnostic capacity of their perception is poor. Hence, this
method is not useful in diagnosing non-adherence in clinical
practice.
Asking patients to report on their own medication adher-
ence also leads to inaccurate estimates. A number of question-
naires available to diagnose adherence are easy to implement,
cheap and widely available [21]. Of around 20 different pa-
tient self-reported questionnaires validated to some extent for
use in hypertension, the four-item Morisky Adherence
Questionnaire (MAQ) is perhaps the most commonly used.
The expanded version of Morisky Medication Adherence
Scale (MMAS), Hill–Bone Compliance Scale, Medication ad-
herence questionnaire and Medication Adherence Self
Efficacy Scale (MEMS) are also used [22•]. However, their
internal validity varies (Cronbachs’s α 0.61–0.91) and their
specificity is generally below 75%. Adherence is overreported
by up to 20% when compared to an objective measure [23].
These overestimates may be due to a number of reasons, for
example social desirability (wanting to be seen as a ‘good’
patient). Thus, questionnaires have an advantage of providing
some insights into barriers of non-adherence [7•] but are not
associated with prediction of cardiovascular outcomes [9•,
24]. Due to the limitations highlighted above, questionnaires




Review of Pharmacy Database Records Acquisition of
medications by patients is considered as a surrogate of adher-
ence to treatment. The most common type of this measure is
medical possession ratio (MPR) defined as the number of days
of medication supplied to the number of days in the observa-
tion multiplied by 100 [25]. MPR >80% is generally consid-
ered as the threshold of good adherence as there is some ev-
idence that it predicts future hospitalisation [26]. Pharmacy
database records are a popular method of assessing adherence;
they can provide some insights into various components of
non-adherence including persistence and discontinuation rates
[27•, 28–32]. The prevalence rates of non-adherence assessed
through review of pharmacy database records range between
14 and 76%; the association with increased risk of cardiovas-
cular outcomes varies [27•, 28–32]. A high variation may
reflect (at least in part) inherent limitations of this method in
diagnosing non-adherence. For example, the accuracy of non-
adherence detected also depends on the completeness and
robustness of the records. A systematic review of pharmacy
patient records has revealed that significant medication errors
were noted in all studies [33]. There was an error rate of
between 13 and 29% in the retention of discontinued medica-
tions on the records, and 24% of medication lists errors were
classified as significant [33]. The accuracy of adherence
assessed using pharmacy records also depends on patients
having access to only monitored systems of medications
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supply and the integration of data across the monitored sys-
tems of prescription refill. The correlation between pharmacy
refill records and an objective measure of testing for non-
adherence (electronic monitoring) is poor [34]. Furthermore,
retrospective pharmacy records may not be reflective of a
patient’s current disease condition, medication taking pattern
or behaviour. Finally, obtaining information from pharmacy
records may be difficult where primary health care records are
not integrated across various systems/providers and electronic
records are not ubiquitously used.
Pill Counting This indirect measure of adherence relies on
counting the number of pills that remain with a patient after a
prescribed period. Pill-counting overestimates non-adherence
by roughly 8% when compared to data from objective elec-
tronic monitoring devices [23]. Although in theory it is a sim-
ple method, it is entirely dependent on the patient’s coopera-
tion (bringing their pill containers to the clinic), it does not
take into account any surplus medication the patient may have
from previous prescriptions, and it is time consuming in a
busy clinical setting [21]. It is also often difficult to determine
the baseline number of pills with a patient and is open to
inadvertent omission due to pills being stored in different
places [35]. Patients may also remove pills when a clinic visit
is due in order to mask non-adherence. Hence, this method is
not commonly used to assess non-adherence in clinical
practice.
Electronic Monitoring Devices Electronic monitoring de-
vices (EMDs) can be broadly divided into devices that record
adherence and those that also provide feedback to the patient
and/or the health care provider. They range from simple au-
diovisual alarm devices, digital recorders with display, to so-
phisticated devices which use pill dispensers with electronic
sensors activated by the act of opening. Feedback may be
provided in the form of audiovisual alerts, prompts on com-
puter systems or wirelessly through text messaging and mo-
bile phones. These data can be transmitted to the patient, their
relatives, their health care provider or support care providers
[36•]. Medication event monitoring systems (MEMS) is the
most widely used EMD; it provides a rich granularity of data
on dosing times, patterns of non-adherence including lack of
initiation of medication, persistence and discontinuation pe-
riods, and periods of good and poor adherence [37]. It has
been widely used in research studies [38•]. There is limited
data available on the ability of non-adherence detected in
EMDs to predict adverse cardiovascular outcomes. The recent
meta-analysis of prospective epidemiological studies on non-
adherence to cardiovascular therapy included one small study
that used an EMD [9•]. The study demonstrated that the like-
lihood of adverse outcomes was decreased in patients with
heart failure who had good adherence [39]. However, EMDs
are expensive and each device can currently monitor only one
medication. Therefore, it is difficult to assess overall non-
adherence in patients on multiple medications such as those
with resistant hypertension. Recently, multi-compartment pill
organisers with electronic monitoring have become available
[40]. There are also adhesive labels or thin polymers with
sensors available to attach on blister packs [30, 41]. These
polypharmacy electronic monitoring systems (POEMS) over-
come the limitation of single medication monitoring.
EMDs may undergo mechanical failure, and patients may
take out more than one pill with each opening [42]. There is
also an increased adherence rate reported on initial use of the
devices; thus, EMDsmay to some extent act as intervention in
increasing adherence to medication [35]. Patients often take
their medications outside of their home, and thus, the systems
may be bulky and intrusive to the patient’s privacy [40].
Despite these limitations, EMDs are probably one of the best
indirect objective methods of diagnosing non-adherence [23].
The main issue remains the high cost of the devices and the
fact that device opening does not equate to ingestion of pills.
Direct Methods
Direct methods include directly observed therapy, digital pills
and biochemical measurements in urine or blood.
Directly Observed Therapy Directly observed therapy
(DOT) clinics invite patients to attend the hospital and take
part in sequential ingestion of antihypertensive mediations at
intervals of 1–2 h under direct continuous observation of a
nurse. Twenty-five percent of non-adherent patients were re-
ported to develop symptomatic hypotension when assessed
using this method [43]. There are also anecdotal reports of
non-adherent patients being admitted to intensive care due to
a precipitous drop in blood pressure driven by ingestion of
previously avoided prescribed medications. Apart from safety
concerns, there are other limitations of this method including
costs, logistics and labour (the patients usually have to come
for at least half-a day and be supervised by trained staff).
Digital Pills A recent innovation is the development of pills
with ingestible sensors that emit a signal when activated by
gastric juices. The signal is detected by a patch worn by the
patient, and the information remotely transmitted to a health
care provider. Digital pills have been shown to be effective
where a course of medications is needed for a limited
timeframe such as in tuberculosis [44]. Although these have
been approved for use by the FDA and European Medicines
Agency, there is as yet only a limited uptake of this technique.
It is also not clear how acceptable this technique might be
to patients.
Biochemical Detection of Medications in Urine or Blood
We and others have recently developed an objective method to
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assess non-adherence in bodily fluid samples [38•, 41, 45–50].
The method utilises high performance chromatography-
tandem mass spectrometry (HPLC-MS/MS) which is com-
monly used in forensic toxicological analysis [51, 52].
HPLC-MS/MS-based analysis requires a simple urine/blood
sample. A total of 5–10 ml of urine collected in a plain con-
tainer, frozen and analysed in batches. Our assay tests for the
presence/absence of 40 most commonly prescribed antihyper-
tensive medications [38•]. The non-detection of expected an-
tihypertensive medication in urine is consistent with non-
adherence to the prescribed antihypertensive lasting at least
as long as its four half-lives [53]. This time is different for
each antihypertensive medication dependent on their pharma-
cokinetic profile. For a majority of antihypertensive medica-
tions, this time is in excess of 24 h. For example, the absence
of amlodipine in urine (half-lives, 35–70 h; 4 half-lives, 140–
280 h) means that the medication was not taken for at least
5.8 days prior to the urine sample collection [53].
HPLC-MS/MS ins t r umen t a t i on i s expens ive
(≈$250,000–$300,000) and requires skilled laboratory staff.
These resources are available in most teaching hospitals in
the UK and the same would be true in similar centres across
the Western world. The analytes are stable in urine [50], and
hence, we envisage a model of non-adherence testing with
regional centres where samples could be sent for analysis by
HPLC-MS/MS. Indeed, our laboratory receives samples from
across 20 centres in the UK and has analysed more than 2000
samples to date. A recent predictive modelling study demon-
strated that repeated biochemical screening for non-adherence
to antihypertensive treatment (known as therapeutic drug
monitoring) is cost-effective in the management of resistant
hypertension [54].
Biochemical assessment by HPLC-MS/MS provides only
a snapshot of non-adherent behaviour. The detection of a pre-
scribed antihypertensive medication in blood/urine does not
equate to persistence. Furthermore, the HPLC-MS/MS-based
urine analysis is not immune to “tooth-brush adherence” or
white-coat adherence—sudden improvement of adherence
prior to a clinic visit (similar to the behaviour of patients
brushing their teeth before visiting a dentist) [55].
When to Assess for Non-Adherence
Given the high incidence of non-adherence in patients present-
ing with ‘resistant hypertension’, we would suggest screening
for non-adherence in all such patients [56•]. We have demon-
strated that approximately one in three patients referred for
renal denervation was non-adherent to their antihypertensive
treatment [18•]. The recent data from DENERHTN trial sug-
gest that non-adherence is even more common amongst pa-
tients in whom renal denervation was conducted [57]. Thus, it
is worth considering screening for non-adherence in patients
with resistant hypertension prior to irreversible and expensive
interventions such as renal denervation.
There is a subgroup of patients who are considered to have
refractory hypertension. This is defined as patients who have
uncontrolled blood pressure despite being on ≥5 antihyperten-
sive medications (usually on two diuretics) and under special-
ist care for their hypertension [58]. The prevalence is thought
to be between 3 and 10% of patients referred with uncon-
trolled resistant hypertension to a specialist clinic [59, 60].
The prevalence of refractory hypertension is estimated at
0.5% of all hypertensives [13]. We suggest excluding non-
adherence to BP-lowering therapy by an objective method in
all such patients before classifying them as truly refractory to
antihypertensive medications.
In our experience, the overwhelming number of patients on
monotherapy are likely to be adherent and therefore, non-
adherence testing is unlikely to be of benefit or cost-
effective in this group of patients. Conversely as the number
of medications increase, it is more likely that patients are non-
adherent. Therefore, it would be useful to test for non-
adherence if there is a lack of an expected response in blood
pressure in patients on optimal antihypertensive therapy, even
if they do not satisfy the definition of resistant hypertension.
Which Interventions Improve Non-Adherence?
A Cochrane review of interventions with a potential to im-
prove non-adherence was published in 2012 [61•]. Only 13
studies related to non-adherence to antihypertensive treat-
ment were of sufficient quality to be included in this review.
Of these, four used self-reported measures of non-adherence,
five used pill counts and the remaining four used MEMS to
monitor non-adherence. Adherence rates improved by 3%
(pill counts) to 36% (self-report) in 11 of the 13 studies.
Systolic BP improved by 3–9.5 mmHg in seven studies,
and in two studies, only diastolic BP improved by 3–
4 mmHg [61•]. There were seven studies that showed im-
proved adherence and a significant change in BP. The inter-
ventions that were of benefit were complex and included
various combinations of detailed patient education or discus-
sion, simplifying dose regime, patient-reported BP measure-
ments, telephone discussions and lifestyle advice [61•]. The
findings of the review are in keeping with the WHO view
that non-adherence needs to be considered in a holistic man-
ner [7•]. All barriers such as difficulty in access to health
care, cost of medications, lack of social support, inadequate
health care provider, patient education (especially for asymp-
tomatic diseases such as hypertension), lack of training of
health care providers, complexities of medication dosing and
co-morbidities including depression need to be addressed
[7•]. Furthermore, any intervention needs to be underpinned
by a tailored approach, that is focused on a patient’s
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concerns and beliefs about hypertension and medications is
formulated [62•]. The Cochrane review concluded that over-
all, the quality of research was poor and emphasised the
need to use objective measures of non-adherence in future
research in this field [61•].
Our Clinical Experience
We have been using urine HPLC–MS/MS analysis in rou-
tine clinical practice for the last 4 years. We collect urine
samples from the patients with their prior consent on the
day of their clinic visit. The results of the analysis are
then discussed at the subsequent appointment. Through
its unbiased nature, the urine analysis provides the physi-
cians with necessary confidence to discuss non-adherence
and its causes. Such discussions are conducted in a non-
confrontational and a non-judgmental manner further to
the biochemical confirmation of the non-adherence to an-
tihypertensive treatment. We explain to patients that the
lack of medications in the body is the reason why their
blood pressure is high. This simple linkage, in our expe-
rience, often changes the perception of patients about the
benefit of medications in controlling their hypertension.
We also address patient beliefs about medications. A key
misconception is that because there are no symptoms of
the disease (hypertension is mostly asymptomatic) and/or
there is actual improvement in well-being, the persistence
with antihypertensive medications is assumed to be un-
necessary [7•, 62•]. Common reasons of non-adherence
[7•] such as forgetfulness and polypharmacy are also ad-
dressed, and simple cost-effective solutions such as a pill
organiser, reminder techniques and/or the reduction in the
number of prescribed medications (combination pills) are
suggested. The HPLC-MS/MS-based urine analysis is per-
formed on follow-up appointments.
The Ethical, Clinical and Economic Aspects
of Screening for Non-Adherence to Antihypertensive
Treatment
There may be concerns that objective testing is similar to
‘policing’ the patients and reflects a disciplinary society
where hierarchical organisations have the dominant power
and individuals lose control of their self and their privacy
[63]. The alternative view is that such monitoring (espe-
cially digital) is part of information society that individ-
uals are willing to be part of and thus gain personal ben-
efit [64]. From the clinical point of view, ignoring or
ineffective way of testing for non-adherence will result
in unnecessary treatment escalations and additional inves-
tigations, many of which carry risks. From the health
economy point of view, the consequences of ineffective
diagnostic approaches to non-adherence to antihyperten-
sive treatment are extremely expensive reaching approxi-
mately $1000 to $1500 per pat ient in the UK.
Improvement in non-adherence rates in hypertensive pa-
tients by 25% can lead to reduction of adverse events by
more than 2 million and lead to savings of $20billion
[65]. On the individual level, detecting non-adherence ob-
jectively prevents unnecessary investigations, hospital
visits and helps bringing to the surface the patient’s views
about medications and their understanding of their illness
which can then be discussed openly in a patient-centred
manner. In our experience, patients are very rarely con-
cerned about the urinary screening for adherence.
Anecdotally, we have had similar feedbacks from other
clinicians across UK who use our service to detect non-
adherence by HPLC-MS/MS.
Conclusion
Non-adherence to BP-lowering therapy is common in pa-
tients with uncontrolled hypertension and is much higher
in patients with ‘resistant hypertension’ than in the gener-
al hypertensive population. Therefore, testing for non-
adherence in these patients should become a part of rou-
tine clinical practice. In our view, subjective methods to
assess non-adherence such as patients’ reports should be
used with caution. Objective measures are more reliable
but are more expensive. Amongst the indirect objective
measures, EMDs with patient feedback provided by a
health care provider are to be preferred over pharmacy
records but the usage would be dictated by resources.
Some direct methods such as DOT are expensive and
can lead to hypotensive events. In our view, the biochem-
ical analysis by HPLC-MS/MS, if available, is the most
accurate and practical technique for use in busy clinics.
Due to the non-invasive nature of collection of urine, the
latter is preferred to blood. The confirmation of non-
adherence to antihypertensive treatment should be follow-
ed by appropriate management centred on a Perceptions
and Practicalities Approach to adherence support en-
dorsed by the NICE Medicine Adherence Guidelines
[12]. Ultimately, achieving sustained adherence is likely
to require a no-blame approach facilitating a Perceptions
and Practicalities Approach to adherence support en-
dorsed by the NICE Medicine Adherence Guidelines
[12]. Ultimately, achieving sustained adherence is likely
to require a no-blame approach facilitating an open dis-
cussion to identify and address the perceptions (e.g. be-
liefs about illness and treatment) and practicalities (e.g.
capability and resources) influencing the patient's motiva-
tion and ability to adhere to antihypertensive treatment.
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